Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma

Developing a Clinical Decision Model: MR Spectroscopy to Differentiate Between Recurrent Tumor and Radiation Change in Patients with New Contrast-Enhancing Lesions

(2009) Ethan A. Smith et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Low-Grade Gliomas: Do Changes in rCBV Measurements at Longitudinal Perfusion-weighted MR Imaging Predict Malignant Transformation?

(2009) Nasuda Danchaivijitr et al.   RADIOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

(2008) Suja Saraswathy et al.   JOURNAL OF NEURO-ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY

Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors

(2008) Eric S. Paulson et al.   RADIOLOGY

Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

(2008) Meng Law et al.   RADIOLOGY